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Summary: Evans syndrome is an underdiagnosed condition con-
sisting of simultaneous or sequential combination of autoimmune
hemolytic anemia and immune-mediated thrombocytopenia. We
report a case of severe Evans syndrome presenting as altered
mental status, a rare presenting sign of the disease. This case
highlights the difficulty in diagnosing Evans syndrome and pro-
vides a review of the literature and management strategies for
treating the disorder.
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OBSERVATIONS
A 13-year-old white boy with a history of idiopathic
thrombocytopenic purpura was transferred to our facility
following an admission at an outside hospital for altered
mental status (AMS). His history of present illness was
significant for 3 days of headache, photosensitivity,
decreased appetite, and fatigue as well as 2 days of jaundice,
pale skin color, and increased bruising in his upper
extremities. On day of admission he was found to be
drowsy and unresponsive to simple commands. The patient
had a history of idiopathic thrombocytopenic purpura,
described as intermittent and self-limited petechiae for the
previous 3 years. At the outside emergency room, the
patient was intubated due to his AMS. Bloodwork was
performed and he received intravenous fluids and empiric
antibiotics. The patient was then transferred to the pedia-
tric intensive care unit at our institution.
The patient was febrile, tachycardic, and hypotensive
on admission. Upon physical examination, the patient was
orally intubated and sedated. He withdrew from painful
stimuli but remainder of neurological examination was
limited due to sedatives. Pupils were equal round and
reactive to light with icteric conjunctivae. No palpable
lymphadenopathy was present. Respiratory examination
demonstrated ventilated breath sounds that were mildly
diminished at the bases. Cardiovascular examination was
significant for tachycardia and a regular rhythm without
murmurs, rubs, or gallops. Hypoactive bowel sounds were
noted with hepatomegaly and splenomegaly present. Skin
was pale and jaundiced throughout with purpura noted
over lower extremities, abdomen, and arms and petechiae
over the anterior thighs bilaterally.
Initial laboratory values were significant for hypo-
albuminemia, hypoproteinemia, hyperbilirubinemia, mild
transaminitis, elevated lactate dehydrogenase and uric acid,
and elevated inflammatory markers. Hematological studies
were notable for white blood cells 32.7/mm3 (51% neu-
trophils, 16% bands, 11% lymps), hemoglobin 3.7 g/dL,
hematocrit 10.5 g/dL, platelets 481, red cell distribution
width 20.1/mm3, mean corpuscular volume 66.5, with
marked polychromasia and spherocytes. Activated partial
thromboplastin time 29.9 seconds, international normalized
ratio 1.7, and prothrombin time 18.4 seconds. Direct
coombs, anti-human globulin, anti-IgG, and anticompli-
ment were all positive. Head computed tomography (CT)
and magnetic resonance imaging revealed a likely calcifi-
cation or microhemorrhage in the left caudate and posterior
temporal lobe. Abdominal CT and abdominal ultrasound
were consistent with hepatosplenomegaly and peripancre-
atic lymphadenopathy (Fig. 1). Chest radiograph was with
normal limits. Electroencephalography did not show seiz-
ure activity.
Initial management at our institution consisted of
packed red blood cell transfusion, high-dose methyl-
prednisolone, intravenous immunoglobulin (IVIG), pro-
phylactic famotidine, and empiric treatment with vanco-
mycin, ceftriaxone, and acyclovir. Pediatric infectious
disease, hematology, immunology, and rheumatology were
FIGURE 1. Computed tomography of the abdomen demon-
strating hepatosplenomegaly.
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consulted. On hospital day 1 the patient’s mental status
gradually improved and he was extubated. Antimicrobials
were discontinued when cultures and CSF studies returned
negative on hospital day 2. The patient’s mental status
returned to baseline on hospital day 2 following improve-
ment of his anemia.
Given the patient’s autoimmune hemolytic anemia and
history of immune-mediated thrombocytopenia, a diagnosis of
Evans syndrome was made. The patient’s AMS was believed
to be due to his severe anemia rather than the possible
microhemorrhage found on CT. Following his clinical
improvement, steroids were discontinued and he was started
on mycophenolate mofetil (MMF). An extensive workup was
performed while in the hospital to determine the underlying
cause of his Evans syndrome. The patient was eventually dis-
charged home 11 days after admission on a maintenance
regimen of MMF. Several weeks after discharge, immunologic
studies drawn before immune therapties returned revealing
underlying diagnosis of common variable immune deficiency.
The diagnosis was made due to diminished circulating B cells,
decreased serum IgG and IgA, and subtherapeutic response to
immunizations.
CONCLUSIONS
The case above highlights the difficulty in diagnosing
Evans syndrome. The condition was first described in 1949
by Evans and Duane, who reported on 24 patients with
acquired hemolytic anemia and thrombocytopenic pur-
pura.1 Evans syndrome is currently defined as the simul-
taneous or sequential combination of autoimmune hemo-
lytic anemia and immune mediated thrombocytopenia with
a positive direct antiglobulin and exclusion of other inde-
pendent causes of the patient’s symptoms. Due to the rarity
of the condition, epidemiological data is lacking on
the condition and the prevalence and incidence of Evans
Syndrome. Interestingly, a retrospective review of 237 cases
of pediatric autoimmune hemolytic anemia revealed a
diagnosis of Evans syndrome in 37% of cases.2 The dis-
order is likely underdiagnosed and has been described in all
sexes, ages, and ethnic groups.
Evans syndrome is believed to be due to either primary
or secondary dysregulation of both the cellular and
humoral immune responses. Approximately 50% of cases
are primary or idiopathic in origin. However, Evans syn-
drome is believed to be a phenotypic bicytopenic pre-
sentation of an underlying immune disease process and
primary or idiopathic cases are likely related to undiag-
nosed immune disorders. The secondary causes of Evans
syndrome are broad and often involve immune-mediated
pathologic disease processes (Table 1). The differential
diagnosis in the workup of Evans syndrome includes
ADAMS-13 deficiency, hemolytic uremic syndrome,
Kasaback-Merritt syndrome, paroxysmal nocturnal hemo-
globinuria, and primary autoimmune lymphoproliferative
disorder. Retrospective review of Evans syndrome is com-
plicated by evidence that previous cases of the condition
may have been due to previously undiagnosed autoimmune
lymphoproliferative disorder.3
Common variable immunodeficiency (CVID) can be
difficult to diagnose, particularly in the setting of ther-
apeutic immune suppression. The diagnosis of CVID is
based on 4 criteria: age above 4 years, low serum IgG with
or without low serum IgA, diminished antibody response to
immunizations, and exclusion of other potential immune
diseases.14 Therapeutic immune modulation for treatment
of cytopenias or hemolysis can alter the immune systems
assays. Patients will often receive IVIG, which will affect
antibody levels, as all as other immunosuppressives that can
affect humoral immune testing (steroids, MMF, rituximab,
etc.). Diagnostic testing should be performed before
immune suppression or specific therapies taken into
account when treatment must be performed before workup.
Evans syndrome is characterized by frequent exacer-
bations that can spontaneously resolve and often follows a
chronic waxing and waning course.4,15,16 Diagnosis is often
delayed, likely due to the rarity and variability in time
course of the disease. The second presentation of cytopenia
can occur months to years following the presentation of the
first cytopenia, as was the case with our patient. Given the
lack of controlled trials for Evans syndrome, therapeutic
options remain highly variable (Table 2).5,16 The mainstay
of treatment of Evans syndrome is immune suppression and
most patients respond well to the treatment. First-line
therapies consist of glucocorticoids and IVIG. Second-line





































Monoclonal gammopathy of undetermined significance
Plasma-cell myeloma
Other




Recombinant interleukin 2 therapy
Tripeptidyl-peptidase II deficiency
therapy consists of immunosuppressive agents or chemo-
therapy. Severe or refractory disease can be treated with
splenectomy or bone marrow transplantation.
Of note, patients with Evans syndrome secondary to
CVID may have a varying response to treatment, including
increased response to rituximab, compared with those with
idiopathic disease.1,6,16,17,24,25 Splenectomy is controversial in
CVID patients, who already have an underlying humoral dis-
order. Removal of the spleen, though an effective treatment for
CVID-related cytopenias, comes at the risk of increased infec-
tion. One study of 48 patients with CVID and refractory
cytopenia demonstrated splenectomy resulted in increased
severe infections (meningitis, sepsis, fungal infections, peri-
tonitis) and nonfatal surgical complications.26 CVID patients
may also have systemic disease manifestations including gas-
trointestinal (both infectious and noninfectious), pulmonary
symptoms (including both restrictive and obstructive lung dis-
ease), and other symptoms related to various infections. As
noted above, CVID patients are at increased risk for infection,
and it is possible that the immune response triggering hemolysis
is due to recent or concurrent infectious processes.25,27,28
Therefore, CVID patient may require differential treatment and
follow-up compared with those with traditional or idiopathic
Evans syndrome.
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